<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302025</url>
  </required_header>
  <id_info>
    <org_study_id>ML41591</org_study_id>
    <nct_id>NCT04302025</nct_id>
  </id_info>
  <brief_title>A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations</brief_title>
  <official_title>NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy and safety of targeted therapies in participants with&#xD;
      resectable Stage IIA, IIB, IIIA, and select IIIB (T3N2) resectable and untreated non-small&#xD;
      cell lung cancer (NSCLC) tumors with selected molecular alterations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Major Pathologic Response (MPR)</measure>
    <time_frame>After surgical resection (approximately study Week 8)</time_frame>
    <description>MPR is defined as &lt;/=10% residual viable tumor cells as scored by local pathologists</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with MPR as Scored by a Central Pathology Committee</measure>
    <time_frame>After surgical resection (approximately study Week 8)</time_frame>
    <description>MPR is defined as &lt;/=10% residual viable tumor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Regression Based on Weighted % Viable Tumor Cell Assessment</measure>
    <time_frame>After surgical resection (approximately study Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed Response Objective Response Rate (ORR) per RECIST v1.1</measure>
    <time_frame>After neoadjuvant treatment (after approximately study Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR) as Assessed by Local and Central Pathology Laboratories</measure>
    <time_frame>At the time of surgical resection (approximately study Week 8)</time_frame>
    <description>Defined as the absence of any viable tumor in main tumor bed at the time of surgical resection, as assessed by local and central pathology laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>From the first date of no disease to local or distant recurrence or death from any cause, whichever occurs first, through the end of the study (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>From first dose of study treatment to first documented disease progression per RECIST v1.1, or local or distant disease recurrence as determined by investigator, or death from any cause, whichever occurs first, through the end of study (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose of study medication to death from any cause, through the end of the study (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ctDNA Clearance Rate</measure>
    <time_frame>Prior to surgery (before study Week 8)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ALK Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROS 1 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTRK Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRAF Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RET Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Participants will receive oral alectinib twice per day (BID)</description>
    <arm_group_label>ALK Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Participants will receive oral entrectinib daily</description>
    <arm_group_label>NTRK Cohort</arm_group_label>
    <arm_group_label>ROS 1 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Participants will receive oral vemurafenib BID</description>
    <arm_group_label>BRAF Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Participants will receive oral cobimetinib daily</description>
    <arm_group_label>BRAF Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Participants will receive surgical resection of the primary tumor along with selected lymph nodes</description>
    <arm_group_label>ALK Cohort</arm_group_label>
    <arm_group_label>BRAF Cohort</arm_group_label>
    <arm_group_label>NTRK Cohort</arm_group_label>
    <arm_group_label>RET Cohort</arm_group_label>
    <arm_group_label>ROS 1 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician</description>
    <arm_group_label>ALK Cohort</arm_group_label>
    <arm_group_label>BRAF Cohort</arm_group_label>
    <arm_group_label>NTRK Cohort</arm_group_label>
    <arm_group_label>RET Cohort</arm_group_label>
    <arm_group_label>ROS 1 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralsetinib</intervention_name>
    <description>Participants will receive oral pralsetinib daily</description>
    <arm_group_label>RET Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Neoadjuvant Therapy:&#xD;
&#xD;
          -  Pathologically documented NSCLC: Stage IIA, IIB, IIIA, or selected IIIB, including&#xD;
             T3N2, or T4 (by size criteria, not by mediastinal invasion) NSCLC (based on the 8th&#xD;
             edition of the American Joint Committee on Cancer [AJCC] Non-Small Cell Lung Cancer&#xD;
             Staging system&#xD;
&#xD;
          -  Molecular testing results from CLIA-certified laboratories and showing at least one of&#xD;
             the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600&#xD;
             mutation; RET fusion&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST v1.1&#xD;
&#xD;
          -  Evaluated by the attending surgeon prior to study enrollment to verify that the&#xD;
             primary tumor and any involved lymph nodes are technically completely resectable and&#xD;
             verify that the participant is medically operable&#xD;
&#xD;
          -  Adequate pulmonary function to be eligible for surgical resection with curative intent&#xD;
&#xD;
          -  Adequate cardiac function to be eligible for surgical resection with curative intent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Male participants must be willing to use acceptable methods of contraception&#xD;
&#xD;
          -  Female participants of childbearing potential must agree to use acceptable methods of&#xD;
             contraception&#xD;
&#xD;
        Inclusion Criteria for Adjuvant Therapy&#xD;
&#xD;
          -  Participants whose tumors lack radiographic progression&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by&#xD;
             virtue of N3 disease&#xD;
&#xD;
          -  Any prior therapy for lung cancer, including chemotherapy, targeted therapy,&#xD;
             immunotherapy, or radiotherapy, within 2 years&#xD;
&#xD;
          -  Participants with prior lung cancer that have been in remission for &lt;2 years with the&#xD;
             exception of minimally invasive adenocarcinoma or incidental typical carcinoid tumors&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Participants known to be positive for HIV are excluded if they meet any of the&#xD;
             following criteria: CD4+ T-cell count of &lt;350 cells/microliters; detectable HIV viral&#xD;
             load; history of an opportunistic infection within the past 12 months; on stable&#xD;
             antiretroviral therapy for &lt;4 weeks&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment, including but&#xD;
             not limited to hospitalization for complications of infections, or any active&#xD;
             infection that, in the opinion of the investigator, could impact participant safety&#xD;
&#xD;
          -  Pregnant or lactating, or intending to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML41591 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center - Deerfield Beach</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute; Brigham and Women's Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care; Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine; Sitemann Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laura and ISAAC Perlmutter Cancer Center at NYU Langone.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University; Hemat/Onc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Pralsetinib</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

